Using Real-World Evidence Enterprise-Wide

Biopharma companies have turned to real-world evidence (RWE) and the real-world data (RWD) it is generated from to support clinical trials and market access efforts, especially as health technology assessment (HTA) bodies increasingly encourage its use in regulatory decision-making. In a recent article in Deloitte, industry leaders discuss how RWE use has extended enterprise-wide and across all stages of  drug life-cycles.

According to the article, “RWE has now evolved into a true “end-to-end” capability. Ninety percent of survey respondents stated their organization is attempting to leverage RWE for decision-making across the product life cycle today.”

To read more, click here.

(Source: Deloitte, September 21^st, 2022)